The Cooper Companies

What The Cooper Companies does

The Cooper Companies, Inc. (NASDAQ: COO) is a global medical device company founded in 1958 and headquartered in San Ramon, California, operating through two principal business units: CooperVision and CooperSurgical. CooperVision manufactures and sells a complete portfolio of contact lenses — daily disposables (MyDay, MiSight 1 day), monthly silicone hydrogel lenses (Biofinity, Biofinity Energys), toric and multifocal options, and rigid gas permeable orthokeratology lenses (Paragon CRT) — serving approximately 43 million wearers globally and holding roughly 25% of the U.S. contact lens market. Its MiSight 1 day is the first and only soft contact lens approved by the FDA, Japan's MHLW, and China's NMPA to slow the progression of myopia in children, with clinical data showing approximately 59% reduction in myopia progression over three years.

CooperSurgical provides fertility and women's health products, including Paragard (the sole non-hormonal copper IUD on the U.S. market), a broad IVF device portfolio, PGTai preimplantation genetic testing using AI-assisted embryo analysis, California Cryobank and Donor Egg Bank USA reproductive tissue services, newborn stem cell banking, and surgical devices for obstetrics and gynecology. The company sells primarily through direct enterprise field sales to optometrists, ophthalmologists, fertility clinics, hospitals, and surgical centers in over 130 countries, with manufacturing in Puerto Rico, Costa Rica, New York, and the UK. Revenue in fiscal 2025 was $4.09 billion, with Q2 2026 revenue up 8% year-over-year to $1.08 billion.

The company has pursued an active acquisition strategy to build CooperSurgical, completing the $1.6 billion Generate Life Sciences deal in 2022, the $300 million Cook Medical Reproductive Health acquisition in November 2023, ZyMöt Fertility in 2024, and obp Surgical for approximately $100 million in August 2024. In December 2025, Cooper announced a strategic review under pressure from activist investors Jana Partners and Browning West, with the potential divestiture of CooperSurgical under evaluation; a new Board Chair (Colleen Jay) and additional independent directors were installed in early 2026. The company is currently profitable with FY2025 operating income of $687 million and employs more than 15,000 people globally.

Name

The Cooper Companies

Legal name

The Cooper Companies, Inc.

Website

https://coopercos.com

Company type

Public

Founded year

1958

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Cooper Companies (NASDAQ: COO) is a global medical device company operating through CooperVision, the world's #1 contact lens manufacturer by wearers serving ~43 million patients with daily, monthly, and myopia control lenses, and CooperSurgical, which provides fertility, IVF, women's health, and Paragard IUD products across 130+ countries with FY2025 revenue of $4.09 billion.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Optical Goods Retailers (45613), Ophthalmic Goods Merchant Wholesalers (42346)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)

akta.pro secondary industry

Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD)

Keywords

• Contact lens manufacturing
• Medical device products
• Myopia control lenses
• Fertility and IVF products
• Women's health devices

Headquarters

HQ city

San Ramon

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Contact Lens Sales (CooperVision): Sale of contact lenses including daily disposables, monthly lenses, specialty toric and multifocal lenses, and myopia control lenses. CooperVision is the world's leading contact lens manufacturer by wearers
2. Women's Health/Fertility Products (CooperSurgical): Sale of fertility devices, IVF products, contraceptives including Paragard IUD, newborn stem cell banking, and women's health surgical devices

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

The Cooper Companies is a global medical device company that manufactures and sells contact lenses through its CooperVision business unit (including daily disposables, monthly silicone hydrogel lenses, myopia control lenses, and orthokeratology lenses) and fertility and women's health products through its CooperSurgical business unit (including Paragard IUD, IVF products, preimplantation genetic testing, donor sperm and egg banking, and newborn stem cell banking). The company sells primarily to eye care professionals and healthcare providers globally.

Product overview

The Cooper Companies is a global medical device company operating through two business units: CooperVision (contact lenses) and CooperSurgical (fertility and women's health). CooperVision offers a complete portfolio of contact lens products including daily disposables (MyDay®, MiSight® 1 day), monthly lenses (Biofinity®, Biofinity Energys®), and orthokeratology lenses (Paragon CRT®), addressing conditions like myopia, astigmatism, presbyopia, and irregular corneas. CooperSurgical provides fertility and women's health solutions including PGTai genetic testing technology, California Cryobank and Donor Egg Bank USA for reproductive tissue, Paragard copper IUDs, newborn stem cell banking, and surgical devices. The portfolio also includes acquired brands: obp Surgical, ZyMöt Fertility, Cook Medical Reproductive Health, and Generate Life Sciences. The company employs over 15,000 people across 130 countries with revenues of approximately $4.1 billion.

Differentiator

Problem solved

Functional benefit

Brands

• MiSight: Myopia control contact lenses for children
• Biofinity
• MyDay
• California Cryobank
• Donor Egg Bank USA
• PGTai
• Paragon CRT
• Biofinity Energys

Products and services

• MiSight 1 day Daily disposable soft contact lens for myopia control in children aged 8-12, FDA-approved to both correct vision and slow the progression of myopia. First and only soft contact lens with this indication in Japan, United States, and China.
• MyDay MiSight 1 day Daily disposable contact lens combining MiSight ActivControl technology with MyDay advanced silicone hydrogel material for myopia control in children, demonstrating approximately 50% reduction in myopia progression.
• Biofinity
• Biofinity Energys
• MyDay
• Paragon CRT
• Paragard Copper intrauterine device (IUD) for long-acting reversible contraception, FDA-approved and marketed by CooperSurgical for pregnancy prevention.
• PGTai (PGT-Complete) Preimplantation genetic testing technology that helps select the highest quality embryo for transplant using AI-assisted analysis, resulting in improved outcomes for fertility patients.
• California Cryobank Sperm bank providing donor sperm with extensive screening and qualification processes for individuals and families building through assisted reproduction.
• Donor Egg Bank USA Egg bank network providing donor eggs for IVF treatments, serving individuals and families including those facing premature ovarian failure, low ovarian reserve, same-sex families, and others.
• Newborn Stem Cells Newborn stem cell preservation services through state-of-the-art labs offering parents options to preserve stem cells from umbilical cord blood and tissue.
• obp Surgical Products Single-use cordless surgical retractors and illuminated suction devices acquired by CooperSurgical in August 2024 for approximately $100 million, expanding the surgical portfolio.
• ZyMöt Fertility Products Advanced reproductive technology products acquired by CooperSurgical in June 2024 to strengthen the fertility portfolio.
• Cook Medical Reproductive Health Products Reproductive health medical devices acquired from Cook Medical in November 2023 for $300 million, expanding CooperSurgical's fertility device offerings.
• Generate Life Sciences Services Fertility and women's healthcare services acquired in 2022 for $1.6 billion from GI Partners, with approximately $250 million in annual revenues at time of acquisition.

Quantifiable outcome

• MiSight reduces myopia progression by approximately 59% after three years of clinical use
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• obp Surgical CorporationcoreOthers · 1 August 2024Acquisition of obp Surgical for approximately $100 million, expanding CooperSurgical portfolio with single-use cordless surgical retractors and illuminated suction devices.
• ZyMöt FertilitycoreOthers · 1 June 2024CooperSurgical acquired ZyMöt Fertility to strengthen fertility portfolio with advanced reproductive technologies.
• Cook Medical (Reproductive Health business)coreOthers · 1 November 2023CooperSurgical acquired Cook Medical's Reproductive Health business for $300 million to expand fertility portfolio.
• New England College of Optometry (NECO)coreStrategic or Co-development Partner · 1 January 2023Partnership to provide extended myopia treatment for under-resourced children in Boston and Massachusetts through community health clinics affiliated with NECO.
• Massachusetts College of Pharmacy and Health Sciences (MCPHS)coreStrategic or Co-development Partner · 1 January 2023Partnership to elevate myopia management within affiliated community health clinics in Boston and Massachusetts region.
• Illinois College of Optometry (ICO)coreStrategic or Co-development Partner · 1 January 2023Partnership through Illinois Eye Institute to expand myopia management with Chicago Public Schools, building on ICO's history of community care.
• The Noble PaperieminorGTM or Marketing Partner · 1 January 2023Partnership to create greeting cards supporting families dealing with infertility, with proceeds partially donated to RESOLVE: The National Infertility Association.
• Generate Life SciencescoreOthers · 1 November 2021CooperCompanies acquired Generate Life Sciences (created by GI Partners in 2018) for $1.6 billion to expand offerings in fertility treatments and reproductive services.
• Plastic BankcoreStrategic or Co-development Partner · 1 January 2021Net plastic neutrality partnership where CooperVision funds collection and recycling of ocean-bound plastic equivalent to weight of plastic in contact lens products. Partnership extended through 2026 and expanded to include vision care program for collectors in Indonesia.
• California CryobankcoreOthers · 1 January 2021CooperCompanies acquired California Cryobank as part of Generate Life Sciences acquisition to expand sperm banking and reproductive services.

Scale indicators12 records

Recent moves7 records

Expansion highlights4 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/85738

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries9 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Cooper Companies